Barinthus Biotherapeutics plc.
BRNSNasdaq
$0.56
↓ -17.1%Jul 17 close · end-of-day
Price
1Y↓ -60.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$22.7M
Enterprise Value
-$43.2M
P/E
—
P/S
—
P/B
0.3
EV/EBITDA
—
PEG
—
FCF Yield
-160.7%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$52.3M
Free Cash Flow (TTM)
-$36.5M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-78.8%
ROIC
-8181.8%
Debt / Equity
—
Net Cash
$65.9M
Return 1Y
-63.7%
Company profile
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.
- CEO
- William Enright
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 107
- Website
- www.barinthusbio.com
Earnings
BRNS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.14↓ -71.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $4.8M | $268,000.00 | $44.7M | $802,000.00 | $15.0M | $0.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$20.0M | -$45.2M | -$4.0M | -$83.9M | -$68.0M | -$70.6M |
| Net income | -$17.7M | -$50.9M | $5.3M | -$73.3M | -$61.1M | -$66.4M |
| Diluted EPS | -$2.24 | -$1.96 | $0.14 | -$1.91 | -$1.55 | -$1.64 |
| Operating cash flow | -$11.0M | -$32.6M | -$14.4M | -$50.9M | -$28.9M | -$48.0M |
| Free cash flow | -$11.3M | -$33.7M | -$20.6M | -$56.3M | -$29.8M | -$48.0M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -415.8% | -16873.5% | -9.0% | -10463.1% | -454.1% | — |
| Net margin | -367.3% | -18979.5% | 11.9% | -9145.5% | -408.0% | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $15.0M | $0.00 | — | — | $0.00 | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$18.3M | -$9.4M | -$23.4M | -$20.6M | -$23.3M | -$15.1M | -$11.6M | -$6.1M |
| Net income | -$16.9M | -$8.1M | -$20.5M | -$19.6M | -$21.1M | -$14.6M | -$11.1M | -$5.5M |
| Diluted EPS | -$0.43 | -$0.21 | -$0.51 | -$0.49 | -$0.52 | -$0.36 | -$0.27 | -$0.14 |
| Operating cash flow | -$12.0M | -$18.2M | $13.1M | -$14.9M | -$18.1M | -$10.7M | -$4.2M | -$3.4M |
| Free cash flow | -$12.2M | -$18.3M | $12.8M | -$14.9M | -$18.1M | -$10.7M | -$4.2M | -$3.4M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | -62.7% | — | — | — | — | — | — |
| Net margin | — | -54.2% | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.